10-Q: Aspira Womens Health Reports Q2 Loss, Nasdaq Delisting

Aspira Womens Health Inc. reported a reduced net loss for the second quarter of 2025, driven by significant operating expense reductions, despite a slight revenue decrease and Nasdaq delisting.

Summary

• Aspira Womens Health Inc. reported a net loss of $4,519,000 for the six months ended June 30, 2025, a 45% improvement compared to a net loss of $8,159,000 for the same period in 2024.
• Total revenue for the six months ended June 30, 2025, increased by 2% to $4,683,000, up from $4,576,000 in the prior year, primarily due to an increase in Average Unit Price (AUP) despite a 7.3% decrease in OvaSuite test volume.
• Gross profit margin improved significantly to 66.1% for the six months ended June 30, 2025, compared to 57.6% for the same period in 2024, largely due to an 18% decrease in cost of product revenue.
• Operating expenses decreased by 31% to $8,144,000 for the six months ended June 30, 2025, down from $11,738,000 in the prior year, driven by substantial reductions in sales and marketing (56%) and general and administrative (20%) expenses.
• The company was delisted from Nasdaq on April 15, 2025, due to not meeting the minimum $2.5 million stockholders' equity requirement, and its common stock now trades on the OTC QB Venture Market.
• The Advanced Research Projects Agency for Health (ARPA-H) terminated a $10 million contract award for the ENDOinform development program on June 9, 2025, citing failure to meet Milestone 3 specifications.
• As of June 30, 2025, the company had cash and cash equivalents of $1,545,000, an accumulated deficit of $535,916,000, and a working capital deficit of $412,000, leading to substantial doubt about its ability to continue as a going concern.
• A material weakness in internal control over financial reporting related to contract review processes and accounting for complex financial transactions continues to exist as of June 30, 2025.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the Nasdaq delisting, termination of a significant government contract, persistent going concern doubts, and ongoing material weakness in internal controls. While net losses decreased and gross margin improved, these operational and financial challenges present substantial risks and overshadow the positive financial trends.

Positives

• Net loss significantly improved by 45% to $4,519,000 for the six months ended June 30, 2025, compared to $8,159,000 in the prior year.
• Gross profit margin increased to 66.1% for the six months ended June 30, 2025, up from 57.6% in the same period of 2024, indicating improved efficiency in cost of revenue.
• Total operating expenses decreased by 31% ($3,594,000) for the six months ended June 30, 2025, primarily due to significant reductions in sales and marketing (56%) and general and administrative (20%) costs.
• Sales per full-time equivalent salesperson increased by 156% in the second quarter of 2025 compared to the second quarter of 2024, following a salesforce rebalance.
• The expansion of the OvaWatch mass monitoring feature in Q2 2024 increased the addressable market for tests tenfold, from approximately 200,000-400,000 to 2-4 million tests per year.
• Product revenue increased by 2% to $4,683,000 for the six months ended June 30, 2025, driven by an increase in Average Unit Price (AUP) for Ova1Plus and OvaWatch tests.

Negatives

• The company was delisted from Nasdaq on April 15, 2025, due to failure to maintain a minimum of $2.5 million in stockholders' equity, and now trades on the OTC QB Venture Market.
• The ARPA-H contract award for the ENDOinform development program, which would have provided $10 million in funding, was terminated on June 9, 2025, as the company did not meet Milestone 3 specifications.
• The company continues to incur significant net losses and negative cash flows from operations, with a net loss of $4,519,000 and cash used in operations of $4,836,000 for the six months ended June 30, 2025.
• Substantial doubt exists about the company's ability to continue as a going concern within one year, given its cash position of $1,545,000, accumulated deficit of $535,916,000, and working capital deficit of $412,000 as of June 30, 2025.
• A material weakness in internal control over financial reporting related to contract review processes and accounting for complex financial transactions persists as of June 30, 2025.
• OvaSuite test volume decreased by 7.3% to 11,407 tests for the six months ended June 30, 2025, compared to 12,300 tests in the prior year, attributed to a reduced field sales headcount.

Risks

• Ability to continue as a going concern due to significant net losses and negative cash flows from operations.
• Reliance on raising additional capital through equity offerings, debt financings, warrant exercises, collaborations, licensing, grants, and strategic alliances, with no assurance of availability on acceptable terms.
• Impacts from potential changes to coverage and reimbursement rates for Ova1 through Medicare Administrative Carrier.
• Failures by third-party payers to reimburse for products and services or changes to reimbursement rates.
• Ability to continue developing existing technologies and to develop, protect, and promote proprietary technologies.
• Ability to comply with FDA regulations and obtain necessary clearances or approvals for medical devices.
• Ability to develop and commercialize additional diagnostic products and achieve market acceptance.
• Ability to compete successfully in a competitive and rapidly changing environment.
• Ability to maintain sufficient or acceptable supplies of immunoassay kits from suppliers.
• Political, economic, and other conditions affecting other countries if products are commercialized outside the United States.
• Changes in healthcare policy and compliance with environmental laws.
• Ability to comply with additional laws and regulations applicable to the operation of Aspira Labs.
• Ability to use net operating loss carryforwards due to potential ownership change limitations (Section 382).
• Ability to successfully defend proprietary technology against third parties and obtain licenses if proprietary rights are asserted.
• Liquidity and trading volume of common stock, especially after delisting from Nasdaq.
• Concentration of ownership of common stock.
• Ability to retain key employees.
• Business interruptions or force majeure events.
• Effectiveness and availability of information systems and cybersecurity risks.
• Ability to integrate and achieve anticipated results from any acquisitions or strategic alliances.
• Future litigation, including intellectual property infringement and product liability exposure.
• Additional costs required for further improvements to laboratory operations.
• Material weakness in internal control over financial reporting related to contract review processes and accounting for complex financial transactions.

Future Outlook

The company plans to continue expending resources on selling and marketing OvaSuite and developing additional diagnostic tests and service capabilities. It expects to incur a net loss and negative cash flows from operations for the remainder of 2025. Management anticipates raising capital through various sources, including equity offerings, debt financings, and strategic alliances, to fund operations. The product pipeline focuses on advancing OVAinform for ovarian cancer risk assessment and continuing the development of ENDOinform for endometriosis, despite the termination of ARPA-H funding for the latter. The company also aims to expand access to its tests, advocate for legislation, and improve its Aspira Synergy platform.

Management Comments

• We expect revenue to increase in the second quarter due to our focus on revenue generating payers.
• We expect research and development expenses to increase modestly over the third quarter of 2025, as a result of our focus on the product pipeline.
• We expect sales and marketing expenses to remain flat during the third quarter of 2025.
• We expect general and administrative expenses to decrease during the third quarter of 2025 as a result of decreases in our consulting and public company costs.

Industry Context

Aspira Womens Health operates in the competitive and rapidly evolving medical diagnostics industry, specifically focusing on gynecologic diseases. The company's strategy to develop and commercialize noninvasive, AI-powered tests for ovarian cancer and endometriosis aligns with broader industry trends towards precision medicine, early detection, and less invasive diagnostic methods. The expansion of OvaWatch's features and the development programs for OVAinform and ENDOinform reflect a commitment to innovation in biomarker-based diagnostics. The termination of the ARPA-H contract highlights the challenges in securing external funding for advanced research, even for promising health solutions. The company's reliance on its CLIA-certified lab and distribution agreements with partners like BioReference Health and ARUP Laboratories is a common model in the diagnostic services sector.

Comparison to Industry Standards

• The company's gross profit margin of 66.1% for the six months ended June 30, 2025, shows improvement over the prior year's 57.6%, indicating better cost management relative to revenue, which is a positive trend in the diagnostics industry where cost efficiency is crucial.
• The significant reduction in sales and marketing expenses (56%) and general and administrative expenses (20%) suggests a strong focus on cost control, which can be a competitive advantage, especially for smaller companies in the medical device and diagnostic sector.
• The tenfold increase in the addressable market for OvaWatch, from 200,000-400,000 to 2-4 million tests per year, positions the company for substantial growth potential, aligning with industry efforts to expand diagnostic reach for prevalent conditions.
• The delisting from Nasdaq to the OTC QB Venture Market indicates a failure to meet standard financial benchmarks for larger exchanges, which can impact investor confidence and access to capital compared to industry peers listed on major exchanges like Hologic, Myriad Genetics, or Exact Sciences.
• The termination of the ARPA-H contract, a significant government funding source, suggests a setback in the development timeline or validation of the ENDOinform program, potentially lagging behind competitors who successfully secure such grants or advance their pipeline projects without major interruptions.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently a party to any legal proceeding, the adverse outcome of which would have a material adverse effect on its financial position or results of operations as of June 30, 2025.

Related Party Transactions

• On December 1, 2023, the company entered into a consulting agreement with Biodesix, Inc., where Jack Schuler, a beneficial owner of more than 5% of the company's stock, is also a beneficial owner of more than 10% of Biodesix, Inc.'s stock. $125,000 in costs have been recorded under this agreement as research and development expense.
• Jack Schuler purchased $200,000 of the Convertible Notes issued in the March 2025 Private Placement.
• Purchasers of the Convertible Notes are entitled to three representatives on the company's board of directors; Jeffrey Cohen, M.D. and John Fraser were appointed as directors on April 2, 2025, and April 6, 2025, respectively, exercising this right.

Stakeholder Impact

• **Shareholders:** Experience significant dilution from ongoing equity offerings and warrant conversions. The Nasdaq delisting reduces liquidity and visibility, potentially impacting share price. Continued net losses and going concern doubt pose substantial risk to investment value.
• **Employees:** Salesforce rebalance resulted in reduction of field sales representatives in non-profitable markets, indicating potential job insecurity or restructuring. Stock-based compensation is a component of overall compensation.
• **Customers (Physicians/Patients):** Continued development of diagnostic tests like OVAinform and ENDOinform aims to provide improved diagnostic aids for gynecologic diseases. Expansion of OvaWatch features increases access to monitoring options.
• **Creditors:** The 'substantial doubt' about the company's ability to continue as a going concern increases credit risk. The DECD loan has specific conditions regarding maintaining Connecticut operations.
• **Suppliers:** The company's financial health and liquidity challenges could impact its ability to meet payment obligations to suppliers, though no specific issues are noted.

Next Steps

• Continue working on the design, development, and commercial launch of the ENDOinform test despite ARPA-H contract termination.
• Increase patient sample testing to refine the algorithm for the OVAinform development program.
• Refine features on the droplet digital PCR commercial platform for miRNA detection for OVAinform.
• Seek additional capital through equity offerings, debt financings, warrant exercises, collaborations, licensing arrangements, grants, government funding, and strategic alliances.
• Address the material weakness in internal control over financial reporting by continuing remediation activities, including retaining outside accounting assistance for complex transactions.
• Expand testing capabilities of Aspira Labs, Inc. to other gynecologic conditions with high unmet need.
• Advocate for legislation and professional society guidelines to broaden access to products and services.

Key Dates

Recommendation

The company faces severe financial distress, evidenced by the 'substantial doubt' about its ability to continue as a going concern, a significant accumulated deficit, and negative cash flows. The delisting from Nasdaq to the OTC QB Venture Market severely limits liquidity and investor access. The termination of the $10 million ARPA-H contract is a major setback for a key development program. While there are some positive trends in reduced net losses and improved gross margin, these are overshadowed by the fundamental issues of financial viability, governance concerns (material weakness in internal controls), and the inability to secure critical funding. The ongoing need for capital raises, coupled with the current market conditions and operational challenges, presents an extremely high-risk profile. A seasoned investor would likely view these factors as indicative of significant downside risk and recommend selling.

Keywords

Aspira Womens Health, AWHL, diagnostic tests, ovarian cancer, endometriosis, OvaSuite, Ova1Plus, OvaWatch, ENDOinform, OVAinform, SEC filing, 10-Q, financial results, Nasdaq delisting, capital raise, medical diagnostics, biomarkers, CLIA laboratory, AI-powered tests